Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BI 765049 |
Synonyms | |
Therapy Description |
BI 765049 is a bispecific T-cell engager (BiTE) that targets tumor-expressed NCR3LG1 (B7-H6) and CD3 expressed on T-cells, potentially leading to increased migration of T-lymphocytes to the tumor, resulting in tumor cell apoptosis and decreased tumor growth (J Clin Oncol 40, no. 16_suppl (June 01, 2022) TPS3175-TPS3175). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BI 765049 | BI-765049|BI765049 | CD3 Antibody 99 | BI 765049 is a bispecific T-cell engager (BiTE) that targets tumor-expressed NCR3LG1 (B7-H6) and CD3 expressed on T-cells, potentially leading to increased migration of T-lymphocytes to the tumor, resulting in tumor cell apoptosis and decreased tumor growth (J Clin Oncol 40, no. 16_suppl (June 01, 2022) TPS3175-TPS3175). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04752215 | Phase I | BI 765049 + Ezabenlimab BI 765049 | A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface | Active, not recruiting | USA | CAN | 0 |